This article contains wording that promotes the subject in a subjective manner without imparting real information. Please remove or replace such wording and instead of making proclamations about a subject's importance, use facts and attribution to demonstrate that importance.(October 2022) ( Learn how and when to remove this message )
Since the 1980s, Evans has launched and supported more than 50 companies in the biotechnology sector, including 20 listed on six different stock markets.[2] Many have specialised in their goal of creating unique products and medicines as well as clinical trials. These include an S-Ketoprofen anti-inflammatory pharmaceutical, single isomer chiral synthons for use in new anti-viral drugs, a single-isomer levobupivacaine for local anaesthesia, the pre-eminent rapid bioluminescent test for bacterial contamination, numerous enzymes and proteins for use in clinical diagnostic tests, as well as stem cell therapies, immunotherapeutics, oncology drugs and respiratory devices.
Evans' first company, Enzymatix, was one of the earliest biotech companies in Europe.[3] Its early work involve the use of cabbages and eggs to mass-produce phospholipids which were used in surfactants to help premature babies breathe.[3] Evans was a co-founder of the biotech business Chiroscience, which was founded in 1991.[4] The company made a number of breakthroughs in the early 1990s. It developed an anesthetic known as Chirocaine,[5] and discovered Romosozumab, which was later acquired by Celltech.[4]
In 1992, Evans was the founder of Celsis, which was based in Cambridge, UK. It specialised in contamination detectors, which included a revolutionary test to detect E.coli in water.[6]Chiroscience became one of the UK's first biotech companies to go public in 1994, when it filed for its initial public offering.[4] Evans remained at the business for another couple of years and left prior to its merger with Celltech in 1999.[4]
Evans founded a number of ventures under the Merlin group. During the 1990s, Merlin focused on partnering with entrepreneurs to create new businesses, in a similar way to how seed funding is now used. Early investments were made in over 20 life science based companies. A £2.5 million investment was made in Cyclacel in 1997.[7]
In 1994, Evans founded Toad, a vehicle technology company specialising in car security devices which went to be a publicly listed company.[8]
In 1997, Evans co-founded ReNeuron, a stem cell research company.[9] The company's research focused on treatments to reverse the effects of neurological diseases.[10]
In 1998, Evans founded Biovex, a company which specialised in the development of a genetically modified herpes virus which kills off cancer cells. The company was ultimately sold to Amgen in 2011 for $1 billion.[11] Later that year, Lord David Puttnam assembled a team of eight trustees for the National Endowment for Science, Technology and the Arts, which included Evans. This later became known as Nesta. It was awarded £200 million by the British government in the 1998 budget.[12] In 2000, ReNeuron was listed on the Alternative Investment Market in a £60 million listing.[10]
In 2004, Vectura a respiratory drug company founded by Evans was listed the Alternative Investment Market. In 2021, The Philip Morris Group made a successful bid of £1billion for the company.[13] Arakis Limited, one of the companies developed by Evans was sold to Sosei Co. Ltd for £106.5 million in 2005.[14]
Evans’ Excalibur Group sold Piramed, which developed treatments for cancer and autoimmune diseases to Roche in 2008 for £$175 million.[15]
In 2013, Evans founded Arthurian Life Sciences, which aimed to bring biotech investment into the Welsh economy.[16] A year later, it worked with the Welsh Government to create and build the Wales Life Sciences Investment Fund, a £100 million 50/50 joint venture life sciences investment fund created to attract business to Wales. The fund has invested in and provided grants to ReNeuron, in which Evans also invested.[17]
In 2015, Evans led the investment funding for Proton Partners International to create the UK's first network of centres offering proton beam therapy, a specialised form of radiotherapy. Proton Partners later became Rutherford Health and Evans remains a non-executive director.[18] In 2016, Evans founded and became deputy chairman of Arix Bioscience, a health and life sciences company investing in medical innovation. The company was listed on the London Stock Exchange with a market cap of £200m in 2017.[19]
In 2017, founded and became chairman of Ellipses Pharma, a company specialising in the development of new cancer drugs.[20]
In 2019, Evans created Excalibur Healthcare Services to specialise in international medical supplies, clinical research and development, diagnostics and testing. The company was formally incorporated in January 2020.[21]
In April 2020, Excalibur was at the forefront of the first phase of a clinical trial which could help diabetics that contract COVID-19.[22] The trial was arranged and structured by Evans. The second phase of the trial received £10 million in funding in August 2020.[23]
Awards
Evans holds 10 honorary professorships, 6 fellowships and a doctorate in sciences. He has been the author of more than 100 scientific publications and patents.[24]
In 1998, he became the youngest recipient of Society of Chemical Industry Centenary medal and was awarded the Henderson Memorial Medal. A year later in 1999, he received the Royal Society of Chemistry Interdisciplinary Medal.[citation needed]
Evans has twice been the recipient of "Cambridge Businessman of the Year" in 1996 and 1998.[25]
He was awarded the OBE in 1995 and knighted in 2001. He was appointed a Honorary Fellow[26] of the Royal Academy of Engineering[26] in 2005. In March of that year, he was appointed by Gordon Brown to the UK Stem Cell Initiative.[27] He made a £1 million loan to the British Labour Party during 2005, which became part of a wider police investigation into party donations,[28] but on 19 July 2007 the UKCrown Prosecution Service announced he was cleared of any wrongdoing.[29]
Personal life
Evans resides in the Cotswolds, and was listed in the Sunday Times Rich List 2020 in 583rd place with an estimated fortune of £208 million. He has a wife and four grown children.[30]
Philanthropy
In 2018, Evans launched the Evamore project, a musical collaboration inspired from the letters of First World War soldiers.[31]
The first release from the project, "One More Yard", was written by Evans and published in November 2018 to mark the centenary of Armistice Day. Sinéad O'Connor sang lead vocals on the track, with supporting vocals by Imelda May. Guitar was played by Ronnie Wood, with Nick Mason playing on drums, whilst instrumentation was provided by Brian Eno and spoken word excerpts recorded by actor Cillian Murphy.[32]
Proceeds from Evamore were donated to The Cancer Awareness Trust, a charity founded by Evans which aims to build ‘useful, reliable and easily understood information’ for use by individuals who have been diagnosed with cancer.[citation needed]
Evans founded The UK Stem Cell Foundation in 2005, a charity focused on funding stem cell research.[33]
Related Research Articles
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.
Chiroscience Group Plc was a British-based biotech company, founded by Christopher Evans. The company was taken over by Celltech in 1999, which was acquired in 2004 by UCB.
Geron Corporation is a biotechnology company located in Foster City, California owned by Geron Hyn Baja of the Philippines, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
Hubert Jacob Paul Schoemaker was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies. In 1999 he founded Neuronyx, Inc., for the manufacture of stem cells and the development of stem-cell therapies.
Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index. Celltech was instrumental in changing the UK's system of technology transfer from research to business, and in creating the biotechnology industry.
Patrick Soon-Shiong is a South African and American businessman, investor, medical researcher, philanthropist, and transplant surgeon. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.
Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The two firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.
Christoph Westphal is an American biomedical businessman.
Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.
Osiris Therapeutics, Inc. was founded in March 1993 following the identification of mesenchymal stem cells (MSCs) by Dr. Arnold Caplan and colleagues at Case Western Reserve University in Cleveland Ohio. Dr. Caplan contributed a license to certain technology and joined Kevin Kimberlin, James S. Burns, a biotech venture capitalist, and Peter Friedli, a lead investor, to launch Osiris; Caplan and Burns had named the company after the Egyptian god of fertility, resurrection, and the afterlife. Early financing was provided by a number of entities, including Three Arch Bay Health Sciences Fund and Spencer Trask & Co. By 1994, the state of Maryland provided a loan and equity investment to lure the company from Ohio in 1995.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Lorenz Studer is a Swiss biologist. He is the founder and director of the Center for Stem Cell Biology at Memorial-Sloan Kettering Cancer Center in New York City. He is a developmental biologist and neuroscientist who is pioneering the generation of midbrain dopamine neurons for transplantation and clinical applications. His expertise in cell engineering spans a wide range of cells/tissues within the nervous system geared toward disease modeling and exploring cell replacement therapy. Currently, he is a member of the Developmental Biology Program and Department of Neurosurgery at Memorial Sloan-Kettering Cancer Center and a Professor of Neuroscience at Weill Cornell Medical College in New York City, NY.
Rutherford Health was a private oncology provider founded by Mike Moran and Karol Sikora in 2015, with investment from Neil Woodford and the Wales Life Sciences Investment Fund, to develop proton therapy facilities in the United Kingdom and elsewhere. Until 2019 it was known as Proton Partners International.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
OvaScience was a publicly traded biotechnology company, focused on female infertility. It was founded in 2011 by Michelle Dipp, Richard Aldrich, Christoph Westphal, Jonathan Tilly, and David Sinclair and is based on scientific work done by Tilly concerning mammalian oogonial stem cells and work on mitochondria by Sinclair. Tilly's work was expectedly met with skepticism, as it warranted a paradigm-shift; however, many labs across the world have been able to reproduce his results over several decades.
Verseon International Corporation is a clinical-stage pharmaceutical company based in Fremont, California. It is developing several drug discovery programs in cardiometabolic diseases and cancer featuring drug candidates that represent novel chemical matter designed using molecular physics and artificial intelligence.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
